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Abstract
Objective: Some previous studies suggest modest to strong effects of 25-
hydroxyvitamin D (25(OH)D) on multiple sclerosis (MS) activity. The objective
of this study was to explore the mechanistic rationale that may explain poten-
tial clinical effects of 25(OH)D. Methods: This study measured serum 25(OH)
D levels and global gene expression proﬁles over a course of up to 2 years in
patients starting treatment with interferon beta-1b (IFNB-1b) after a clinically
isolated syndrome. MS disease activity was assessed by the number of gadolin-
ium-enhancing lesions present on repeated magnetic resonance imaging
(MRIs). Results: The number of gadolinium-enhancing lesions was highly sig-
niﬁcantly associated with 25(OH)D levels. Conducting various systems-level
analyses on the molecular level, multiple lines of evidence indicated that 25
(OH)D regulates expression dynamics of a large gene–gene interaction system
which primarily regulates immune modulatory processes modulating MS activ-
ity. The vitamin D response element was signiﬁcantly enriched in this system,
indicating a direct regulation of this gene interaction network through the vita-
min D receptor. With increasing 25(OH)D levels, resulting regulation of this
system was associated with a decrease in MS activity. Within the complex net-
work of genes that are regulated by 25(OH)D, well-described targets of IFNB-
1b and a regulator of sphingosine-1-phosphate bioavailability were found. The
25(OH)D effects on MS activity were additively enhanced by IFNB-1b. Inter-
pretation: Here, we provide mechanistic evidence that an unbalanced 25(OH)D
gene expression system may affect MS activity. Our ﬁndings support a potential
beneﬁt of monitoring and managing vitamin D levels (e.g., through supplemen-
tation) in early MS patients treated with IFN-beta-1b.
Introduction
There is growing evidence that vitamin D may not only be
important in the development of multiple sclerosis (MS),
a complex demyelinating disease of the central nervous
system, but also in MS disease activity and in its long-term
progression.
1 Several observational studies of patients with
MS have found that increased 25-hydroxyvitamin D (25
(OH)D) levels were associated with fewer relapses
2–4 and
decreased magnetic resonance imaging (MRI) activity.
5
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605Additionally, a number of randomized, placebo-con-
trolled clinical trials of vitamin D supplementation among
patients with MS have reported lower numbers of gado-
linium-enhancing lesions (GELs)
6 and relapses
7 or no
effect of 25(OH)D on any MS endpoint,
8,9 although it
must be noted that many clinical trials did not have sufﬁ-
cient power to detect an effect of 25(OH)D on MS dis-
ease activity. In a longitudinal study among over 450
participants in the Betaferon/Betaseron in Newly Emerg-
ing For Initial Treatment (BENEFIT) clinical trial,
10–12
low 25(OH)D levels (<50 nmol/L) predicted conversion
from a clinically isolated syndrome (CIS) to clinically def-
inite MS (CDMS) and were associated with a higher rate
of new active lesions and a higher relapse rate.
13 How-
ever, the biological mechanisms underlying these observa-
tions are not understood. While 25(OH)D is known to be
an immunomodulator,
14 how it may act on a molecular
level in patients with MS to reduce disease activity is not
known.
Thus, we conducted a global gene expression analysis
in which expression proﬁles at various time points among
participants in the BENEFIT clinical trial were measured
in order to examine the potential relationship between
genes or gene sets expressed in association with 25(OH)D
and those associated with MS activity. Further analysis of
the identiﬁed gene sets to characterize their enrichment
with respect to known 25(OH)D gene sets and enrich-
ment for vitamin D receptor (VDR) binding sites was
performed to help elucidate potential mechanisms for the
mode of action of 25(OH)D in the context of MS.
Subjects and Methods
Ethics statement
BENEFIT was a multicenter study, in which patients from
18 countries were included in 98 centers. The study was
conducted in agreement with Good Clinical Practice
(GCP) principles according to the International Confer-
ence on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use. The
Institutional Review Boards of all participating centers
approved the study protocol and all patients gave written
informed consent before trial entry. The secondary analy-
ses presented in this manuscript were conducted anony-
mously to describe the impact of vitamin D in the
context of interferon beta-1b (IFNB-1b) treatment.
Study population and study design
The BENEFIT study was originally designed to evaluate
the impact of early versus delayed treatment with IFNB-
1b (Betaseron
 ; Bayer HealthCare Pharmaceuticals;
Berlin, Germany) in patients with a ﬁrst event suggestive
of MS (i.e., a diagnosis of a CIS). Between February 2002
and June 2003, 468 patients from 18 European countries,
Israel, and Canada were enrolled at 98 centers. In the ini-
tial placebo-controlled phase, patients with a minimum of
two clinically silent lesions on MRI, and thus a high
probability to convert to CDMS,
15 were randomized in a
5:3 ratio to receive either IFNB-1b 250 lg( n = 292) or
placebo (n = 176) subcutaneously every other day for
2 years or until diagnosis of CDMS. All patients were
then eligible to enter a prospectively planned follow-up
phase with open-label IFNB-1b for up to a maximum of
5 years after randomization. Details of the study design
and results have been published elsewhere.
10–12
Measurement of 25(OH)D
25(OH)D was measured in serum samples collected at
baseline (immediately before study treatment in the
placebo-controlled phase of BENEFIT and up to 60 days
after the onset of the CIS) and at 6, 12, and 24 months
thereafter. Under ambient conditions, samples were
shipped within 3 days of being drawn and then maintained
at  20°C at the central laboratory until further analysis.
First thaw process after the initial freeze was completed for
this study. Only samples with a minimum of 2 mL of
serum were included resulting in 465 patients with at least
one, 417 with two or more, 396 with three or more, and
303 with all four 25(OH)D measurements (total of 1570
samples). Serum 25(OH)D was measured using an
enzyme-linked immunosorbent assay (ELISA), which is
sensitive down to 5.0 nmol/L (Immunodiagnostic Systems
Inc., Fountain Hills, AZ). Quality control samples were
included among the study samples and the average
intraassay coefﬁcient of variation (CV) derived from these
samples was 4.4%. The average interassay CV was 11.7%.
Measurement of MS activity
The number of GELs on T1-weighted images from brain
MRI scans performed at screening and months 3, 6, 9,
12, 18, 24 and then yearly in the follow-up study was
used as a measure of MS activity. There were 1494 simul-
taneous 25(OH)D and MRI measurements at the CIS
(baseline) and months 6, 12, and 24 (Fig. 1). MRI scans
were performed as described previously.
10,16
Gene expression
At baseline, month 2 or 3, month 12, and month 24 and
yearly in the follow-up study, blood for analysis of mRNA
expression was collected using the PAXgene system (Pre-
AnalytiX GmbH, Hombrechtikon, Switzerland). Samples
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month 24. Gene expression proﬁles of whole blood were
measured using Affymetrix HGU 133 plus 2.0 (affymetrix,
Santa Clara, CA, USA) arrays according to the manufac-
turer’s protocol. Raw data were RMA robust multi-array
analysis background corrected,
17 quantile normalized,
18
and transformed with a logarithm to base 2. Probe sets
were mapped and summarized to their respective Ensembl
gene ID using custom cdf “HGU133Plus2_Hs_ENSG” ver-
sion 15.1.0 (downloaded from http://brainarray.mbni.med.
umich.edu/Brainarray/Database/CustomCDF/15.1.0/ensg.
asp, accessed 9 October 2012).
19 Global gene expression
proﬁles of ~19,000 genes were available from 295 individu-
als; details on available data are shown in Figure 1 and
Tables S1, S2.
Statistics
To model the number of GELs as a function of 25(OH)D
levels (both as continuous and dichotomized [<50 nmol/
L vs. ≥50 nmol/L] variables), IFNB-1b, and other covari-
ates, generalized linear mixed models were applied using
proc glimmix in SAS version 9.2 (Cary, NC, USA), which
account for the within-person correlation of the repeated
measurements. A compound symmetry structure was used
to model these correlations. Estimators were exponentiat-
ed to give risk ratios (RR). To determine whether 25
(OH)D or IFNB-1b was associated with gene expression,
generalized linear models were used to model gene
expression as a function of 25(OH)D levels, or IFNB-1b,
adjusting for age, sex, treatment at the time of 25(OH)D
measurement, and the interaction of 25(OH)D level and
IFNB-1b. All time points were analyzed together in order
to reﬂect and capture the time-dynamic variation of
mRNA and maximize the power of the analysis. The
genes that were identiﬁed as having expression signiﬁ-
cantly related to levels of 25(OH)D made up the gene
set we named “MS_vitD_genes0.05.” Generalized linear
models were also used to model GEL count as a function
of gene expression to determine the gene set associated
with GEL count. To correct for multiple testing, the Ben-
jamini and Hochberg
20 or Bonferroni
21 methods were
used. For both, a threshold of P ≤ 0.05 was considered
statistically signiﬁcant. R version 2.15.0 was used for all
the analyses related to gene expression.
Gene set analysis
Gene Set Enrichment Analysis (GSEA) was done with the
JAVA implementation of the GSEA preranked tool, as
described previously.
22 Brieﬂy, GSEA is a weighted modi-
ﬁcation of the Kolmogorov–Smirnov test, testing whether
the distribution of test scores within a speciﬁc gene set
signiﬁcantly differs from the null distribution. Previously
published gene sets for comparison were identiﬁed from
the Molecular Signatures Database version 3.1,
22 by
searching for genes annotated with the gene ontology
(GO) terms GO:0071305 – cellular response to vitamin
D; GO:0070563 – negative regulation of VDR signaling
pathway; GO:0070564 – positive regulation of VDR sig-
naling pathway; GO:0070562 – regulation of VDR signal-
ing pathway; or GO:0070561 – VDR signaling pathway
and from two recently published studies on VDR-medi-
ated gene expression.
23,24 A description of each 25(OH)D
gene set identiﬁed and their respective references are in
Table 1. Gene-speciﬁc beta estimators quantifying the
25(OH)D
N=465 with 1,570 
measurements at Baseline, 
Month 6, 12, 24
T1-weighted MRI
N=465 with 4772 measurements 
at Baseline, Month 6, 12, 24 […] 
to Year 5
Gene Expression Proﬁles (GEP)
N=295 with 953 measurements 
at Baseline, Month 6, 12, 24 […] 
to Year 5
GEL-25(OH)D 
Analysis
Gd+ lesions—Gene expression
N=256 with 605 MRI and GEP 
measurements at Baseline, Month 6, 
12, 24 […] to Year 5
Gene Expression 
Analysis
Gene expression—25(OH)D
N=225 with 445 25(OH)D and GEP 
measurements at Baseline, Month 
6, 12, and 24
25(OH)D
N=463 with 1,493 25(OH)D 
and MRI measurements at 
Baseline, Month 6, 12, 24
All Data
Figure 1. Flowchart of available data and size of data partitions used in the different analyses.
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association of 25(OH)D level or IFNB-1b with expression
of a particular gene, estimated from the general linear
models described above, were used as input vectors in the
GSEA tool. For functional gene classiﬁcation, the Data-
base for Annotation, Visualization, and Integrated Discov-
ery (DAVID)
25 was used as follows: the Affymetrix HGU
Plus 2.0 platform was selected as background and default
Table 1. Association of 25(OH)D target gene sets with either 25(OH)D, IFNB-1b treatment or Gd-enhancing lesions in BENEFIT, as determined by
GSEA.
Gene set name Description
Association with 25
(OH)D
Association with
IFNB-1b Association with GELs
NES p/FDR-q value
1 NES p/FDR-q value
1 NES p/FDR-q value
1
KnightUp [2010] Genes that are bound
and upregulated by
the 25(OH)D receptor
2
2.09 0.000/0.000 2.46 0.000/0.000  1.96 0.000/0.004
MS_vitD_genes0.05
Munger et al.
BENEFIT gene expression
proﬁles
3
2.08 0.000/0.000 2.21 0.000/0.000  2.83 0.000/0.000
STAMBOLSKY_RESPONSE_
TO_VITAMIN_D3_
UP [2010]
Genes induced in SKBR3
cells by 25-hydroxyvitamin D3
4
1.58 0.006/0.038 1.47 0.039/0.102 1.15 0.236/0.417
CarlbergUp [2011] Genes that are bound and
upregulated by the
25(OH)D receptor
5
1.54 0.004/0.040  1.06 0.357/0.710 0.64 0.974/0.961
BIOCARTA_VDR_
PATHWAY [2005]
Control of Gene Expression by
Vitamin D Receptor
6
1.44 0.088/0.087  0.93 0.557/0.804  0.84 0.654/0.983
25(OH)D_GO_associated_
genes [2009]
Genes annotated for GO terms
related to Vitamin D
1.36 0.121/0.118 1.42 0.102/0.104 0.92 0.581/0.742
V$DR3_Q4 [2005] Genes with promoter regions
containing the motif
RRTGNMCYTNNTGAMCCNYNT
7
1.01 0.435/0.720  0.77 0.947/0.844 1.16 0.207/0.527
V$VDR_Q3 [2005] Genes with promoter regions
containing the motif
GGGKNARNRRGGWSA
8
0.99 0.500/0.672  1.07 0.267/1.000 1.44 0.002/0.205
V$VDR_Q6 [2005] Genes with promoter regions
containing the motif
CNSNNTGAACCN
9
0.85 0.828/0.897 0.71 0.978/0.897 1.25 0.067/0.469
STAMBOLSKY_RESPONSE_
TO_VITAMIN_D3_
DN [2010]
Genes repressed in SKBR3 cells
(breast cancer) by
25-hydroxyvitamin D3
10
0.77 0.814/0.953 1.03 0.418/0.578 1.15 0.301/0.345
25(OH)D, 25-hydroxyvitamin D; IFNB-1b, interferon beta-1b; BENEFIT, Betaferon/Betaseron in Newly Emerging For Initial Treatment; GSEA, Gene
Set Enrichment Analysis; FDR, false discovery rate; GELs, gadolinium-enhancing lesions; NES, normalized enrichment score.
1FDR < 0.1 designated as statistically signiﬁcant in GSEA analyses.
36
2Set derived from Ramagopalan et al.: 25(OH)D receptor ChIP-Seq and GEP in lymphoblastoid cell line after stimulation with calcitriol for 36 h ?
identiﬁcation of genes that are bound and upregulated by the 25(OH)D receptor.
3Set derived from BENEFIT gene expression proﬁles and 25(OH)D data from the model GeneExpression~25(OH)D*IFNß+covariates. To enter the
set, the particular gene had to have a nominal P-value of ≤0.05.
4Genes induced in SKBR3 cells by 25-hydroxyvitamin D3. From Broad Institute MSigDB v3.1.
5Set derived from Heikkinen et al. 25(OH)D receptor ChIP-Seq after 40-min stimulation with calcitriol and gene expression proﬁling after 4-h stim-
ulation with calcitriol in THP-1 monocytic leukemia cells followed by the identiﬁcation of genes that are bound and upregulated by the 25(OH)D
receptor.
6Control of Gene Expression by Vitamin D Receptor. From Broad Institute MSigDB v3.1, derived from Biocarta.
7Genes with promoter regions [ 2 kb, 2 kb] around transcription start site containing the motif RRTGNMCYTNNTGAMCCNYNT which matches
annotation for VDR: vitamin D (1,25- dihydroxyvitamin D3) receptor. From Broad Institute MSigDB v3.1.
8Genes with promoter regions [ 2 kb, 2 kb] around transcription start site containing the motif GGGKNARNRRGGWSA which matches annota-
tion for VDR: vitamin D (1,25- dihydroxyvitamin D3) receptor. From Broad Institute MSigDB v3.1.
9Genes with promoter regions [ 2 kb, 2 kb] around transcription start site containing the motif CNSNNTGAACCN which matches annotation for
VDR: vitamin D (1,25- dihydroxyvitamin D3) receptor. From Broad Institute MSigDB v3.1.
10Genes repressed in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3. From Broad Institute MSigDB v3.1.
608 ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Vitamin D and Gene Expression in MS K. L. Munger et al.DAVID gene sets were tested with the exception of
“Functional_Categories” and “Protein_Domains.”
Promoter analysis
Using the Multiple Em for Motif Elicitation (MEME)
Suite of motif-based sequence analysis tools,
26 two vita-
min D-responsive elements (VDRE) positional weighted
matrices (PWMs) were inferred from VDR-ChIP sequenc-
ing data recently published by Heikkinen et al.
23 and
Ramagopalan et al.
24 (see Fig. S1). Subsequently, we used
the Find Individual Motif Occurrences (FIMO) tool with
the inferred VDRE PWMs, the VDRE PWM available
from the JASPAR database (ID MA0074.1),
27 and the
consensus Interferon Stimulated Response Element (ISRE)
PWM published by Levy et al.,
28 to screen for either of
these motifs with a P-value detection threshold of 10
 4 in
the upstream sequences database provided by FIMO. Of
note, all three VDRE PWMs are highly similar. However,
we screened for all three of them, since this will some-
what account for natural and context-dependent variabil-
ity of the PWM which is not reﬂected using point
estimates of base frequencies. Using the hypergeometric
distribution, we then computed the probability of ﬁnding
a particular count of VDRE and/or ISRE binding sites in
the upstream sequences of the derived 25(OH)D, IFNB-
1b and GEL-associated genes given the sites genome-wide
background distribution.
Results
Basic characteristics of patients with at least one 25(OH)
D measurement are shown in Table 2. 25(OH)D levels by
visit are shown in Table 3. The comparison of 25(OH)D
levels in patients on IFNB-1b versus placebo at months 6,
12, and 24 did not reveal signiﬁcant differences between
treatment arms. As to be expected, the number of GELs
was higher at baseline as compared to the postbaseline
visits, with more GELs in the placebo group compared
with the IFNB-1b-treated group (Table S3). This differ-
ence gradually decreased from months 6 to 24, likely due,
in part, to the design of the BENEFIT study which
allowed for switching of patients with CDMS in the pla-
cebo group to IFNB-1b treatment.
Number of GELs shows inverse association
with 25(OH)D levels
An increase of 25(OH)D levels by 50 nmol/L was associ-
ated with a statistically signiﬁcantly lower GEL count
(Table 3). Adjusting for gender, age, treatment, and treat-
ment-25(OH)D interaction, the results were unchanged.
Similar results were seen when using dichotomized 25
Table 2. Basic characteristics of the cohort of patients from BENEFIT
with at least one 25(OH)D measurement.
Characteristic Value
N 465
Age, years   SD 31.3   7.5
Female sex, n (%) 329 (71)
Number of patients with at least 1 GEL
at the CIS, n (%)
196 (42)
Number of patients with at least 1 GEL
during the ﬁrst 24 months, n (%)
262 (56)
IFNB-1b treatment at day 1, n (%) 0 (0)
IFNB-1b treatment at month 24, n (%) 303 (78)
BENEFIT, Betaferon/Betaseron in Newly Emerging For Initial Treatment;
25(OH)D, 25-hydroxyvitamin D; SD, standard deviation; GEL, gadolin-
ium-enhancing lesion; CIS, clinically isolated syndrome; IFNB-1b, inter-
feron beta-1b.
Table 3. Risk for GELs by 25(OH)D level.
N Mean Median (IQR)
25(OH)D levels
All 1572
1 49.53 (22.97) 45.34 (33.43–62.04)
Baseline 457 45.87 (17.93) 43.70 (31.55–56.46)
Month 6 359 48.83 (20.14) 46.65 (34.50–60.64)
Month 12 349 43.38 (20.26) 38.25 (29.17–55.08)
Month 24 386 60.30 (28.71) 54.04 (39.02–76.20)
GEL count
2
All 1493 0.89 (2.48) 0.00 (0.00–1.00)
Baseline 453 1.48 (3.38) 0.00 (0.00–1.00)
Month 6 323 0.73 (2.17) 0.00 (0.00–0.00)
Month 12 346 0.66 (1.88) 0.00 (0.00–1.00)
Month 24 371 0.51 (1.68) 0.00 (0.00–0.00)
50 nmol/L increase in 25(OH)D
≥50 nmol/L vs.
<50 nmol/L
Unadjusted Adjusted
3 Adjusted
3
Relative risk of GEL by 25(OH)D level, RR [95% CI], P value
All 0.45 [0.32–0.65],
P < 0.0001
0.43 [0.28–0.66],
P = 0.0001
0.61 [0.44–0.83],
P = 0.002
Baseline 0.39 [0.30–0.49],
P < 0.0001
0.38 [0.30–0.49],
P < 0.0001
–
Month 6 0.66 [0.47–0.93],
P = 0.02
0.29 [0.17–0.50],
P < 0.0001
–
Month 12 0.65 [0.45–0.92],
P = 0.02
0.99 [0.51–1.92],
P = 0.99
–
Month 24 0.70 [0.53–0.93],
P = 0.01
1.03 [0.57–1.87],
P = 0.91
–
GEL, gadolinium-enhancing lesion; 25(OH)D, 25-hydroxyvitamin D;
IQR, interquartile range; RR, risk ratios.
1Note that some 25(OH)D measurements were taken from samples
from visits other than baseline, Months 6, 12, or 24. These were
excluded from further analysis.
2Note that only T1 scans are stated for which a 25(OH)D measure-
ment was available.
3Models were adjusted for age at time of measurement, gender,
treatment, and the interaction of treatment and 25(OH)D level.
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and ≥50 nmol/L, respectively) in the respective model.
Signiﬁcant associations between GEL counts and 25(OH)
D levels were also observed when visits were analyzed sep-
arately, with the lowest RR for the baseline visit, which
had the highest number of GELs and occurred prior to
start of IFNB-1b treatment (Table 3). GEL count as a
function of 25(OH)D level is shown in Figure S2.
25(OH)D and IFNB-1b systemically regulate
25(OH)D target gene sets
Among BENEFIT participants, the expression of 63 genes
was found to be regulated by 25(OH)D based on a nomi-
nal P-value threshold of 0.05 (Table S4). However, none
of these genes remained statistically signiﬁcant after false
discovery rate (FDR) correction for multiple testing with
a P-value threshold of 0.05. These 63 genes made up the
25(OH)D BENEFIT gene set (gene set “MS_vitD_
genes0.05” in Table 1). Of note, one of these genes is
sphingosine-1-phosphate phosphatase 1 (SGPP1), an
enzyme that catalyzes the degradation of sphingosine-1-
phosphate (S1P), the substrate for S1P receptors which
are a prominent therapeutic target in MS.
29,30
The pairwise overlap of the BENEFIT gene set with
other 25(OH)D gene sets (see Subjects and Methods and
Table 1) was negligibly small (in most cases less than
10%), which supports recent ﬁndings that 25(OH)D may
regulate a large number of genes and diverse processes in
a highly context-dependent manner.
24,31–34 By GSEA test-
ing of these 25(OH)D target gene sets, it was determined
that the experimentally derived 25(OH)D gene sets
(Ramagopalan et al.
24 and Stambolsky et al.
34) were highly
enriched (FDR < 0.05). As all normalized enrichment
scores (NES measures the magnitude and direction of a
gene set association with the response) were in the positive
range, this is indicative of a broad and systemic gene
expression upregulation mediated by 25(OH)D (Table 1).
Considering that the rather weak impact of 25(OH)D
on single genes (none remained statistically signiﬁcant
after FDR correction) may have been inﬂuenced by
IFNB-1b-induced gene expression in the BENEFIT cohort,
the magnitude of association between all genes and IFNB-
1b treatment was examined. This analysis detected 770
genes that were signiﬁcantly associated with IFNB-1b
treatment (Table S5). Sixty-two (98%) of the 63 25(OH)
D-associated genes were also signiﬁcantly associated with
IFNB-1b treatment. GSEA analysis of the systemic associ-
ation of IFNB-1b-induced gene expression with gene sets
known to be regulated by 25(OH)D showed that the
experimentally derived 25(OH)D target genes sets
(MS_vitD_genes0.05, KnightUp,
24 and Stambolsky_
response_to_vitamin_D3_up
34) were highly associated
with IFNB-1b gene induction (FDR ≤ 0.1), (Table 1) sup-
porting the hypothesis that a subset of 25(OH)D target
genes are coregulated by IFNB-1b in an additive manner.
Genes and gene sets regulated by 25(OH)D
are associated with reduction of GELs
Given the association between high 25(OH)D levels with
low GEL count, genes regulated by 25(OH)D were exam-
ined with respect to their impact on regulating GELs.
This could provide a systemic rationale for building a
mechanistic model of how 25(OH)D inﬂuences MS activ-
ity. Modeling GELs as function of gene expression, we
found that more than 5000 genes were associated with
GEL count (see Table S6 for the top 347 signiﬁcant genes
remaining after Bonferroni adjustment of P-values), and
there was overlap with more than 50% of the 25(OH)D-
associated genes, as well as 65% of IFNB-1b-associated
genes (Fig. 2A). The vast majority of 25(OH)D-associated
genes were regulated in such a way by 25(OH)D that
would, in turn, reduce GEL count (Fig. 2B–E).
GSEA was performed and revealed that the BENEFIT
25(OH)D gene set (MS_vitD_genes0.05) as well as the
KnightUp gene set
24 were highly associated with GEL
count in such a manner that the upregulation of these
gene sets would result in a reduction of GEL count
(Table 1).
VDRE and ISRE motifs are enriched in genes
associated with 25(OH)D and GELs
Modeling GEL count-related gene expression as a func-
tion of 25(OH)D does not provide causal evidence for a
relationship and the overlap between 25(OH)D- and
IFNB-1b-associated genes may be purely correlative. If
there is a causal relationship of these compounds to the
genes they putatively regulate, appropriate regulatory ele-
ments (namely, VDR response element VDRE and ISRE
sites) should be enriched in the promoter regions of
the respective genes. Hence, a genome-wide screen with
different VDRE and ISRE PWMs using the FIMO tool
provided by the MEME suit was conducted.
With respect to the VDRE, these analyses revealed that
8679 of 43267 (Ensembl GRCh37.p10, February 2009
assembly, April 2013 Genebuild) coding and non-coding
genes have either of the VDR binding sites present in the
sequences upstream of their transcription start site (TSS).
This goes well along with the fact that 25(OH)D-medi-
ated VDR activation has been shown to result in a pleth-
ora of target genes being regulated.
35 Based on this
analysis, it was determined that 36 of the 63 genes associ-
ated with 25(OH)D in BENEFIT contained at least one
VDRE and hence there was a signiﬁcant enrichment of
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set (P = 0.0012). This indicates that a substantial part of
the 25(OH)D-associated genes may directly be regulated
by this secosteroid and implies indirect 25(OH)D-medi-
ated regulation of the remaining 27 genes or the presence
of regulatory elements in regions that were not included
in the analysis (e.g., within exons or introns, the 50 or 30
UTR).
31 Importantly, 25(OH)D-associated genes in the
MS_vitD_genes0.05 gene set also showed signiﬁcant
enrichment for the ISRE motif (P = 0.0009) and addi-
tionally the combination of both sites was overrepresented
in 25(OH)D-associated genes (P = 0.002). This was in
line with the ﬁnding that there was a substantial overlap
of genes associated with 25(OH)D and genes that were
associated with IFNB-1b treatment. For these analyses,
FDR values were within the 0.1 cutoff designated as statis-
tically signiﬁcant in GSEA documentation.
36
Next, enrichment for VDRE and ISRE motifs in genes
that were signiﬁcantly associated with GELs was
determined. FIMO-based analyses of the upstream
a
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Figure 2. IFNB-1b and 25(OH)D-regulated genes are additionally associated with regulating the count of Gd-enhancing lesions. (A) Venn diagram
depicting the overlap between genes that are associated with Gd-enhancing lesions, 25(OH)D or IFNB-1b. (B) Genes whose induction is associated
with a reduction of Gd lesion count and which are upregulated through 25(OH)D and IFNB-1b. (C) Genes whose induction is associated with a
reduction of Gd lesion count and which are downregulated through 25(OH)D and IFNB-1b. (D) Genes whose induction is associated with an
increase of Gd lesion count and which are upregulated through 25(OH)D and IFNB-1b. (E) Genes whose induction is associated with an increase
in Gd lesion count and which are downregulated through 25(OH)D and IFNB-1b. IFNB-1b, interferon beta-1b; 25(OH)D, 25-hydroxyvitamin D.
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revealed that 155 of 347 screened genes contained at
least one VDRE motif (P = 0.014) in the sequence
upstream of their TSS, 204 contained an ISRE motif
(P = 3.8 9 10
 17), and 101 contained both a VDRE and
ISRE motif (P = 2.5 9 10
 6), suggesting a signiﬁcant
enrichment of these sites by themselves and in combina-
tion of MS activity-associated genes.
25(OH)D-regulated and GEL-associated
genes are functionally enriched for
regulation of immune system processes
To complement the single-gene analysis, the biological
processes that were regulated by genes that were associated
with 25(OH)D in the context of MS activity were inferred.
The 63 genes associated with 25(OH)D were analyzed for
enrichment of predeﬁned biological terms using DAVID.
25
The most prominent enrichment cluster represented
gene sets connected to immune responses to pathogens
(Table 4). The terms “defense response to bacterium” and
“defense response” were detected with nominal P-values of
3.9 9 10
 5 and 8.2 9 10
 5, respectively. As expected, the
top enrichment cluster for IFNB-1b-associated genes also
included the term “defense response” (P = 1.1 9 10
 10)
among other immune system related terms.
For GEL count-associated genes, the three most promi-
nent enrichment clusters were all attributable to processes
and pathways of the immune system (inﬂammatory
responses, antigen presentation, and NF-kB signaling).
The term “defense response” which was also associated
with 25(OH)D-associated genes was detected with a P-
value of 2 9 10
 6. These ﬁndings indicate that 25(OH)D
regulates processes that are important for the regulation
of MS activity.
The 25(OH)D gene interaction network is a
component of the MS activity gene
interaction network
In order to gain deeper insight into regulatory interac-
tions and associations between the genes found to be
associated with GELs and/or 25(OH)D, these two gene
sets were analyzed using the Search Tool for the Retrieval
of Interacting Genes/Proteins (STRING).
37 In case of the
25(OH)D-associated genes (Fig. 3A), there is one major
connected component centered around lactotransferrin
(LTF), an iron-binding protein that plays a major role in
immune processes.
38 Various genes in this component
connected the 25(OH)D system to the IFNB-1b system
(e.g., LTF and ELANE). There was a second connected
component centered around “interferon-induced protein
with tetratricopeptide repeats 1” (IFIT1) which was
placed in the central hub-part of the network of genes
associated with GELs. This MS network was characterized
by a large and densely connected hub component that
was particularly enriched for genes connected to inter-
feron response (Fig. 3B).
Discussion
In this large, cross-sectional study of participants in the
BENEFIT trial, GEL count was inversely associated with
25(OH)D levels, with every 50 nmol/L increase in 25
(OH)D being associated with a 55% decreased GEL rate,
although we cannot rule out confounding by other factors
that vary with season such as infections. Of note, seasonal
variation of GELs and inverse associations with 25(OH)D
levels have been previously reported.
5,6,39–41
An important gap in the current knowledge is how 25
(OH)D may act on a molecular level to inﬂuence GEL
development. While previous studies have examined the
expression of speciﬁc 25(OH)D-related genes in patients
with MS
42,43 and numerous studies on gene expression in
MS have been conducted,
44–47 this is the ﬁrst study to
scrutinize the relationship between 25(OH)D-driven gene
expression and MS activity (as assessed by the number of
GELs) over a period of up to 2 years. The results show
that even in a cohort such as BENEFIT, with rather low
Table 4. DAVID enrichment analysis.
Term P-value Adjusted
1 P-value
25(OH)D-associated genes
Defense response to bacterium <0.001 0.024
Defense response <0.001 0.026
Response to bacterium <0.001 0.130
Serine-type endopeptidase activity <0.001 0.022
Serine-type peptidase activity <0.001 0.022
IFNB-1b-associated genes
Defense response <0.001 <0.001
Response to wounding <0.001 <0.001
Inﬂammatory response <0.001 <0.001
Regulation of apoptosis <0.001 0.004
Regulation of programmed cell death <0.001 0.005
GEL-associated genes
Defense response <0.001 0.001
Inﬂammatory response <0.001 0.095
MHC class I protein complex <0.001 0.100
Antigen processing and presentation <0.001 0.140
Regulation of I-kappaB
kinase/NF-kappaB cascade
<0.001 0.140
DAVID, Database for Annotation, Visualization and Integrated Discov-
ery; 25(OH)D, 25-hydroxyvitamin D; IFNB-1b, interferon beta-1b; GEL,
gadolinium-enhancing lesions; MHC, major histocompatibility com-
plex.
1FDR corrected using the Benjamini and Hochberg (BH) adjustment.
20
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sion regulation on bona ﬁde 25(OH)D target gene sets
derived from lymphocyte and monocyte backgrounds.
23
Although on the single gene level, 25(OH)D effects are
relatively minor, the results show that this secosteroid is
an important systemic factor in that its levels regulate
many genes in a subtle fashion which in their sum are
important modulators of gene regulatory networks crucial
in inﬂuencing MS activity.
The analysis of 25(OH)D gene set association with 25
(OH)D levels showed strong gene set upregulation, this
being suggestive of a context-dependent systemic role of 25
(OH)D in reducing GEL count by regulating whole gene
sets to jointly inﬂuence and tune a variety of biological pro-
cesses. Of note, this effect appears to be in addition to that
of the IFNB-1b treatment-induced gene expression changes,
which are known to reduce GEL count
10,48 and whose
effects have been well described in other studies.
44,49,50
Interestingly, some of the 25(OH)D target gene sets are
highly signiﬁcantly associated with reducing GEL count,
an effect that is independent of IFNB-1b treatment. This
effect is also found when looking at the single genes that
are associated with 25(OH)D levels, supporting an addi-
tive effect of both 25(OH)D and IFNB-1b in that they
reduce GEL count more effectively in combination. Addi-
tionally, overrepresentation of VDRE and ISRE motifs in
these genes and generally in genes associated with GEL
count provides evidence of a mechanistic link. In line
with this, the genes associated with 25(OH)D were pre-
dominantly associated with immune regulatory processes
(in agreement with a recent publication by Satoh and
Tabunoki),
51 which are also prominently associated with
MS and IFNB-1b treatment.
44,45,47 One potential mecha-
nism leading to a suppression of MS activity by 25(OH)D
could be the S1P receptor-dependent migration of lym-
phocytes from secondary lymphoid tissues because higher
25(OH)D levels were associated with the expression of
SGPP1, a gene that encodes for an enzyme that catalyzes
the degradation of S1P. Depriving the S1P receptor of its’
normal substrate has been shown to be an effective thera-
peutic strategy in MS.
29,30
25(OH)D involvement in gene expression is known to
be context dependent and there are numerous levels at
which the mode of action and the magnitude of its effects
are ﬁne tuned. Not only does the VDR interact with reti-
noid X receptor and other cotranscription factors,
34 but
its expression and the levels of 25(OH)D metabolizing
enzymes such as CYP24A1 are also regulated by tightly
tuned feedback loops that may be modiﬁed by different
allelic variants of the molecules involved.
52–54 This is also
reﬂected by the quantity of potential 25(OH)D target
genes identiﬁed in different studies which show only min-
imal overlap.
51 Accordingly, effects of 25(OH)D can be
very contrary, reaching from being a proapoptotic agent
to being cytoprotective.
34 Whereas this study provides
evidence that the latter is the case for MS, this ambiguous
A
B
Figure 3. 25(OH)D and MS activity gene interaction networks. The
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was
used to visualize knowledge-based connectivity of genes being
associated with 25(OH)D levels (A) or Gd-enhancing lesion count (B).
Thickness of lines is proportional to the probability of a true interaction of
any pair of genes. 25(OH)D, 25-hydroxyvitamin D; MS, multiple sclerosis.
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target genes tuning in patients with MS.
As a consequence, these may be used as therapeutic
targets that are tunable by 25(OH)D supplementation and
that could be a booster of IFNB-1b treatment efﬁcacy.
It is a particular strength of this study that rigorously
controlled MRI ﬁndings from a clinical trial which was
set up to obtain regulatory approval for the use of IFNB-
1b in patients with a CIS were used. These data are the
ﬁrst to link disease activity with 25(OH)D-related molec-
ular mechanisms in patients with MS. Because MRI
examinations, 25(OH)D measurements, and gene expres-
sion proﬁling were frequently performed simultaneously
within the ﬁrst 2 years of our study, actual inﬂammatory
activity of the disease could be related to 25(OH)D levels
and gene expression proﬁles at the same time point in a
cross-sectional manner.
Limitations of this study shall also be addressed. First,
expression proﬁling was performed in whole blood, as the
selection of peripheral blood monocytes (or even more
speciﬁc lymphocyte populations) was not feasible in a
multicenter study. This certainly added noise to the ﬁnd-
ings and it might well be that stronger and more distinct
gene expression proﬁles could have been obtained if more
speciﬁc cell populations were analyzed. Second, this study
focused on gene expression analyses in the cohort treated
with IFNB-1b right after CIS; only a limited number of
samples obtained under placebo treatment could be
included. Therefore, the impact of IFNB-1b on gene
expression proﬁles was largely based on the difference
between baseline and postbaseline samples in the early
IFNB-1b cohort and, as the baseline sample was obtained
right after the CIS, the impact of the ﬁrst event could be
present in those analyses. Nevertheless, the effect of
IFNB-1b treatment on the observed gene expression pro-
ﬁles was well in line with published evidence.
44,45,47 Third,
vitamin D level was only measured at ﬁxed time points
(baseline, months 6, 12, and 24), and not at the time of
relapses. Relapses at the ﬁxed time points were only
observed occasionally. Therefore, the power to compare
vitamin-D-related gene expression during relapses and
relapse-free periods was too low to perform meaningful
analyses. Fourth, although the present analysis suggests a
direct effect of 25(OH)D on genes associated with GELs,
the possibility of non-VDR-mediated effects that would
be associated with increased 25(OH)D and 25(OH)D-
associated gene expression, such as ultraviolet light expo-
sure, cannot be excluded and could have independently
affected GEL development via non-25(OH)D-related
pathways. Finally, almost all patients in this study were
whites of European ancestry and the majority of partici-
pants were eventually treated with IFNB-1b (although
uniform treatment is an important advantage), thus
limiting generalizations to individuals of other races or
ethnicities or to patients treated with different drugs.
In summary, by analyzing the gene expression, this
study identiﬁed the ﬁrst molecular evidence that immu-
nological effects of 25(OH)D impact disease activity in
patients with very early MS. These ﬁndings should be
deepened by the investigation of more speciﬁc lympho-
cyte subsets and extended to populations in the later
stages of the disease. Furthermore, biological validation of
these results is warranted.
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